A metabolic biosignature of early response to anti-tuberculosis treatment

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Mahapatra, Sebabrata ^a   Hess, Ann M ^a   Johnson, John L ^b,c   Eisenach, Kathleen D ^d   DeGroote, Mary A ^a   Gitta, Phineas ^c   Joloba, Moses L ^c,e   Kaplan, Gilla ^b,f   Walzl, Gerhard ^g   Boom, W H ^b,c   Belisle, John T ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e MAKERERE UNIVERSITY   (Uganda)

^f PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Anti tuberculosis therapy; Biomarker; Mass spectrometry; Metabolomics; Mycobacterium tuberculosis, Urine; Small molecule biosignature; Tuberculosis

Indexed keywords

BIOLOGICAL MARKER; CREATININE; TUBERCULOSTATIC AGENT;

ARTICLE; CLINICAL FEATURE; HUMAN; LIQUID CHROMATOGRAPHY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; METABOLOMICS; SOUTH AFRICA; TREATMENT DURATION; TREATMENT RESPONSE; UGANDA; URINALYSIS;

ADULT; ANTITUBERCULAR AGENTS; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; METABOLOMICS; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84893184836     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-53     Document Type: Article

References (47)

1. Wallis RS, Kim P, Cole S, Hanna D, Andrade BB, Maeurer M, Schito M, Zumla A. Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect Dis 2013, 13(4):362-372. 10.1016/S1473-3099(13)70034-3, 23531389.
2. Wallis RS, Pai M, Menzies D, Doherty TM, Walzl G, Perkins MD, Zumla A. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010, 375(9729):1920-1937. 10.1016/S0140-6736(10)60359-5, 20488517.
3. Perrin FM, Lipman MC, McHugh TD, Gillespie SH. Biomarkers of treatment response in clinical trials of novel antituberculosis agents. Lancet Infect Dis 2007, 7(7):481-490. 10.1016/S1473-3099(07)70112-3, 17524807.
4. Nahid P, Saukkonen J, Mac Kenzie WR, Johnson JL, Phillips PP, Andersen J, Bliven-Sizemore E, Belisle JT, Boom WH, Luetkemeyer A, et al. CDC/NIH workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am J Respir Crit Care Med 2011, 184(8):972-979. 10.1164/rccm.201105-0827WS, 3208659, 21737585.
5. Walzl G, Ronacher K, Djoba Siawaya JF, Dockrell HM. Biomarkers for TB treatment response: challenges and future strategies. J Infect 2008, 57(2):103-109. 10.1016/j.jinf.2008.06.007, 18649943.
6. Beisel WR. Metabolic response to infection. Annu Rev Med 1975, 26:9-20. 10.1146/annurev.me.26.020175.000301, 1096783.
7. Zhang A, Sun H, Wang P, Han Y, Wang X. Modern analytical techniques in metabolomics analysis. Analyst 2012, 137(2):293-300. 10.1039/c1an15605e, 22102985.
8. Vinayavekhin N, Homan EA, Saghatelian A. Exploring disease through metabolomics. ACS Chem Biol 2010, 5(1):91-103. 10.1021/cb900271r, 20020774.
9. Theodoridis GA, Gika HG, Want EJ, Wilson ID. Liquid chromatography-mass spectrometry based global metabolite profiling: a review. Anal Chim Acta 2012, 711:7-16.
10. Catchpole G, Platzer A, Weikert C, Kempkensteffen C, Johannsen M, Krause H, Jung K, Miller K, Willmitzer L, Selbig J, et al. Metabolic profiling reveals key metabolic features of renal cell carcinoma. J Cell Mol Med 2011, 15(1):109-118. 10.1111/j.1582-4934.2009.00939.x, 19845817.
11. Kim K, Aronov P, Zakharkin SO, Anderson D, Perroud B, Thompson IM, Weiss RH. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics 2009, 8(3):558-570. 10.1074/mcp.M800165-MCP200, 2649817, 19008263.
12. Wang-Sattler R, Yu Z, Herder C, Messias AC, Floegel A, He Y, Heim K, Campillos M, Holzapfel C, Thorand B, et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol 2012, 8:615. 3472689, 23010998.
13. Rhee EP, Gerszten RE. Metabolomics and cardiovascular biomarker discovery. Clin Chem 2012, 58(1):139-147. 10.1373/clinchem.2011.169573, 22110018.
14. Richeldi L. An update on the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2006, 174(7):736-742. 10.1164/rccm.200509-1516PP, 16799073.
15. McNerney R, Maeurer M, Abubakar I, Marais B, Mchugh TD, Ford N, Weyer K, Lawn S, Grobusch MP, Memish Z, et al. Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis 2012, 205:S147-S158. 10.1093/infdis/jir860, 22496353.
16. Zhang H, Il'yasova D, Sztaray J, Young SP, Wang F, Millington DS. Quantification of the oxidative damage biomarker 2,3-dinor-8-isoprostaglandin-F(2alpha) in human urine using liquid chromatography-tandem mass spectrometry. Anal Biochem 2010, 399(2):302-304. 10.1016/j.ab.2009.12.024, 2853187, 20026293.
17. Bain MD, Jones M, Borriello SP, Reed PJ, Tracey BM, Chalmers RA, Stacey TE. Contribution of gut bacterial metabolism to human metabolic disease. Lancet 1988, 1(8594):1078-1079.
18. Nicholls AW, Mortishire-Smith RJ, Nicholson JK. NMR spectroscopic-based metabonomic studies of urinary metabolite variation in acclimatizing germ-free rats. Chem Res Toxicol 2003, 16(11):1395-1404. 10.1021/tx0340293, 14615964.
19. Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrom Rev 2007, 26(1):51-78. 10.1002/mas.20108, 1904337, 16921475.
20. Bollard ME, Stanley EG, Lindon JC, Nicholson JK, Holmes E. NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR Biomed 2005, 18(3):143-162. 10.1002/nbm.935, 15627238.
21. Hesseling AC, Walzl G, Enarson DA, Carroll NM, Duncan K, Lukey PT, Lombard C, Donald PR, Lawrence KA, Gie RP, et al. Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. Int J Tuberc Lung Dis 2010, 14(5):560-570.
22. Mahapatra S, Woolhiser LK, Lenaerts AJ, Johnson JL, Eisenach KD, Joloba ML, Boom WH, Belisle JT. A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD + adduct. Antimicrob Agents Chemother 2012, 56(1):28-35. 10.1128/AAC.05486-11, 3256082, 22037847.
23. Wishart DS, Knox C, Guo AC, Eisner R, Young N, Gautam B, Hau DD, Psychogios N, Dong E, Bouatra S, et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res 2009, 37(Database issue):D603-D610. 2686599, 18953024.
24. Cone EJ, Caplan YH, Moser F, Robert T, Shelby MK, Black DL. Normalization of urinary drug concentrations with specific gravity and creatinine. J Anal Toxicol 2009, 33(1):1-7. 10.1093/jat/33.1.1, 19161663.
25. Preziosi P. Isoniazid: metabolic aspects and toxicological correlates. CurrDrug Metab 2007, 8(8):839-851.
26. Prasad B, Singh S. In vitro and in vivo investigation of metabolic fate of rifampicin using an optimized sample preparation approach and modern tools of liquid chromatography-mass spectrometry. J Pharm Biomed Anal 2009, 50(3):475-490. 10.1016/j.jpba.2009.05.009, 19535209.
27. Yamamoto T, Moriwaki Y, Takahashi S, Hada T, Higashino K. Study of the metabolism of pyrazinamide using a high-performance liquid chromatographic analysis of urine samples. Anal Biochem 1987, 160(2):346-349. 10.1016/0003-2697(87)90058-3, 3578761.
28. Zhu M, Burman WJ, Starke JR, Stambaugh JJ, Steiner P, Bulpitt AE, Ashkin D, Auclair B, Berning SE, Jelliffe RW, et al. Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int J Tuberc Lung Dis 2004, 8(11):1360-1367.
29. Sokolova GB, Ziia AV, Abramovich AG, Bessarabova TN, Ivleva A. Ethambutol pharmacokinetics in pulmonary tuberculosis patients. Farmakol Toksikol 1986, 49(5):40-42.
30. Ehtesham NZ, Nasiruddin M, Alvi A, Kumar BK, Ahmed N, Peri S, Murthy KJ, Hasnain SE. Treatment end point determinants for pulmonary tuberculosis: human resistin as a surrogate biomarker. Tuberculosis (Edinb) 2011, 91(4):293-299. 10.1016/j.tube.2011.04.007, 21606003.
31. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011, 11(5):343-354. 10.1038/nri2960, 21475309.
32. Alsleben N, Ruhwald M, Russmann H, Marx FM, Wahn U, Magdorf K. Interferon-gamma inducible protein 10 as a biomarker for active tuberculosis and latent tuberculosis infection in children: a case-control study. Scand J Infect Dis 2012, 44(4):256-262. 10.3109/00365548.2011.632644, 22103555.
33. Riou C, Perez Peixoto B, Roberts L, Ronacher K, Walzl G, Manca C, Rustomjee R, Mthiyane T, Fallows D, Gray CM, et al. Effect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosis. PLoS One 2012, 7(5):e36886. 10.1371/journal.pone.0036886, 3351475, 22606304.
34. Shui GH, Bendt AK, Jappar IA, Lim HM, Laneelle M, Herve M, Via LE, Chua GH, Bratschi MW, Rahim SZZ, et al. Mycolic acids as diagnostic markers for tuberculosis case detection in humans and drug efficacy in mice. Embo Molecular Medicine 2012, 4(1):27-37. 10.1002/emmm.201100185, 3376831, 22147526.
35. Du Preez I, Loots DT. New sputum metabolite markers implicating adaptations of the host to Mycobacterium tuberculosis, and vice versa. Tuberculosis (Edinb) 2013, 93(3):330-337. 10.1016/j.tube.2013.02.008, 23477940.
36. Garcia-Zamalloa A, Taboada-Gomez J. Diagnostic accuracy of adenosine deaminase and lymphocyte proportion in pleural fluid for tuberculous pleurisy in different prevalence scenarios. PLoS One 2012, 7(6):e38729. 10.1371/journal.pone.0038729, 3377686, 22723878.
37. Mach VJ, Reck R, Ziller R. Diagnostic value of hydroxyproline excretion in bone tuberculosis. Beitr Orthop Traumatol 1973, 20(5):235-239.
38. Phillips M, Basa-Dalay V, Blais J, Bothamley G, Chaturvedi A, Modi KD, Pandya M, Natividad MP, Patel U, Ramraje NN, et al. Point-of-care breath test for biomarkers of active pulmonary tuberculosis. Tuberculosis (Edinb) 2012, 92(4):314-320. 10.1016/j.tube.2012.04.002, 22647661.
39. Banday KM, Pasikanti KK, Chan EC, Singla R, Rao KV, Chauhan VS, Nanda RK. Use of urine volatile organic compounds to discriminate tuberculosis patients from healthy subjects. Anal Chem 2011, 83(14):5526-5534. 10.1021/ac200265g, 21619052.
40. Syhre M, Manning L, Phuanukoonnon S, Harino P, Chambers ST. The scent of mycobacterium tuberculosis-part II breath. Tuberculosis (Edinb) 2009, 89(4):263-266. 10.1016/j.tube.2009.04.003, 19481976.
41. Weiner J, Parida SK, Maertzdorf J, Black GF, Repsilber D, Telaar A, Mohney RP, Arndt-Sullivan C, Ganoza CA, Fae KC, et al. Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients. PLoS One 2012, 7(7):e40221. 10.1371/journal.pone.0040221, 3402490, 22844400.
42. Patti GJ. Separation strategies for untargeted metabolomics. J Sep Sci 2011, 34(24):3460-3469. 10.1002/jssc.201100532, 21972197.
43. Saude EJ, Adamko D, Rowe BH, Marrie T, Sykes BD. Variation of metabolites in normal human urine. Metabolomics 2007, 3(4):439-451.
44. Gagneux S, Small PM. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis 2007, 7(5):328-337. 10.1016/S1473-3099(07)70108-1, 17448936.
45. Nicol MP, Wilkinson RJ. The clinical consequences of strain diversity in Mycobacterium tuberculosis. Trans R Soc Trop Med Hyg 2008, 102(10):955-965. 10.1016/j.trstmh.2008.03.025, 18513773.
46. Oppermann M, Damoc NE, Crone C, Moehring T, Muenster H, Hornshaw M. High precision measurement and fragmentation analysis for metabolite identification. Methods Mol Biol 2012, 860:145-156.
47. Bowen BP, Northen TR. Dealing with the unknown: metabolomics and metabolite atlases. J Am Soc Mass Spectrom 2010, 21(9):1471-1476. 10.1016/j.jasms.2010.04.003, 20452782.